- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Ophthalmology
Volume 2012 (2012), Article ID 786870, 7 pages
doi:10.1155/2012/786870
Anti-VEGF Treatment Strategies for Wet AMD
1Department of Ophthalmology, Bascom Palmer Eye Institute, School of Medicine, University of Miami, 311 9th St North, Naples, FL 34102, USA
2Penn State Hershey Eye Center, Hershey, PA 17033, USA
Received 1 July 2011; Revised 20 September 2011; Accepted 23 October 2011
Academic Editor: James T. Handa
Copyright © 2012 Jaclyn L. Kovach et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.